Abstract:Key PointsAttempts to target RAS pharmaceutically have not yet yielded small molecules with sufficient potency and drug-like characteristics to be useful, but additional approaches are underway.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.Inhibitors of RAS effector signalling are currently centred on the RAF–MEK–ERK and PI3K–AKT–TOR pathways, with many inhibitors of components of these two pathways under clinical evaluation. The less well-studied effector pathways that lead to activation of RAL and RAC small GTPases are also promising targets.Despite some setbacks owing to issues of reproducibility, functional screens for synthetic lethal interactors with oncogenic RAS remain an attractive approach to identify novel drug targets for RAS-driven cancers.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.

Drugging the Ral GTPase.

RAL GTPases: Biology and Potential As Therapeutic Targets in Cancer

Discovery and Characterization of Small Molecules That Target the Ral GTPase

Discovery and characterization of small molecules that target the GTPase Ral

One Step Closer to Targeting RAS.

Drugging Ras GTPase: a Comprehensive Mechanistic and Signaling Structural View.

Advances in the Development of Rho GTPase Inhibitors

Drugging Ras Gtpase: A Comprehensive Mechanistic And Signaling Structural View

Developing Small Molecules that Inhibit K-Ras/GTP Binding Based on New Affinity Measurements

Drugging the undruggable RAS: Mission Possible?

Drugging K-RasG12C through covalent inhibitors: Mission possible?

Pharmacologic restoration of GTP hydrolysis by mutant RAS

In Silico Design of Novel RGS2-Galpha-q Interaction Inhibitors with Anticancer Activity

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance

Small Activating RNA Modulation of the G Protein‐Coupled Receptor for Cancer Treatment

Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

Signaling Through Rho GTPase Pathway As Viable Drug Target.

Automated NMR Fragment Based Screening Identified a Novel Interface Blocker to the LARG/RhoA Complex

Targeting Ras-, Rho-, and Rab-family GTPases via a conserved cryptic pocket